Immunocore (IMCR) vs Replimune Group (REPL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Replimune Group (REPL) has outperformed Immunocore (IMCR) over the past year, gaining 183.9% versus a loss of 14.1%. Over five years, IMCR leads with a -22.6% price change compared with -56.2% for REPL. Immunocore is the larger company by market cap ($1.51 billion vs $1.24 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMCR | REPL |
|---|---|---|
| Share price | $29.41 | $13.20 |
| Market cap | $1.51B | $1.24B |
| 1-day change | -0.47% | -0.38% |
| YTD return | -15.27% | +35.80% |
| 1-year return | -14.06% | +183.87% |
| 5-year return | -22.61% | -56.22% |
| EPS (TTM) | $-0.36 | $-3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.72 | $16.33 |
| 52-week low | $27.56 | $1.50 |
| Distance from 52-week high | -27.77% | -19.17% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +113.29% | +47.73% |
| Average volume | 449.06K | 4.20M |
| Shares outstanding | 51.50M | 94.22M |
| Employees | 524 | 465 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- REPL has outperformed IMCR by 197.9 percentage points over the past year.
About Immunocore
IMCR stock →Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Healthcare · Biotechnology · 524 employees
About Replimune Group
REPL stock →Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Healthcare · Biotechnology · 465 employees
IMCR vs REPL FAQ
Which is bigger, Immunocore or Replimune Group?
Immunocore (IMCR) is larger, with a market capitalization of $1.51B compared with $1.24B for Replimune Group (REPL).
Which stock has performed better over the past year, IMCR or REPL?
REPL returned +183.87% over the past 12 months, compared with -14.06% for IMCR (price return, excluding dividends). Past performance does not predict future results.
Are Immunocore and Replimune Group in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.